Microbubble Contrast Agents Using Ultrasound

 

Deepika Maliwal 1* and Vidyasagar Patidar 2

1Dept. of Pharma. Chemistry, 2Dept. of Pharmaceutics, B. R. Nahata College of Pharmacy, Mandsaur

 

 

ABSTRACT

Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast agents to traditional medical sonography

Ultrasound contrast agents are gas-filled micro-bubbles that are administered intravenously to the systemic circulation. The field of Contrast-enhanced ultrasound is expanding rapidly with exciting new applications. While ultrasound contrast agents were initially used to overcome insufficient transcranial bone windows for identification of the basal cerebral arteries, new-generation micro-bubbles in combination with very sensitive contrast-specific ultrasound techniques now enable real-time visualization of stroke. This article will provide a review of recent and emerging developments in ultrasound technology and contrast-specific imaging techniques.

 

 KEY WORDS              Contrast-enhanced ultrasound, ultrasound contrast agents.                                                                  

 


INTRODUCTION:

Contrast-enhanced     ultrasound     (CEUS)     is     the

application of ultrasound contrast agents to traditional medical  sonography.  Ultrasound  contrast  agents  are gas-filled micro-bubbles that are administered intravenously to the systemic circulation. Micro- bubbles have a high degree of echogenicity, which is the ability of an object to reflect the ultrasound waves. The  echogenicity difference between the  gas  in  the micro-bubbles and the soft tissue surroundings of the body  is  immense.  Thus,  ultrasonic  imaginusing micro-bubble contrast agents enhances the ultrasound backscatter, or reflection of the ultrasound waves, to produce a unique sonogram with increased contrast due to the high echogenicity difference. Contrast-enhanced ultrasound can be used to image blood perfusion in organs, measure blood flow rate in the heart and other organs. Targeting ligand that bind to receptors characteristic of intravascular diseases can be conjugated to micro-bubbles, enabling the micro- bubble complex to accumulate selectively in areas of interest,  such  as  diseased  or  abnormal  tissues.  This form   o molecular   imaging know as   targeted contrast-enhanced ultrasound, will only generate a strong ultrasound signal if targeted microb-ubbles bind in the area of interest. Targeted contrast-enhanced ultrasound can potentially have many applications in both medical diagnostics and medical therapeutics. However, the targeted technique has not yet been approved for clinical use; it is currently under preclinical research and development

 

Microbubble Contrast Agents:

General features

There are a variety of micro-bubbles contrast agents. Micro-

bubbles differ in their shell makeup, gas core makeup, and whether or not they are targeted.

•      Micro-bubble   shell selectio o shell    material determines how easily the micro-bubble is taken up by the immune system. A more hydrophilic material tends to be taken up more easily, which reduces the micro- bubble residence time in the circulation. This reduces the time available for contrast imaging. The shell material also affects micro-bubble mechanical elasticity. The more elastic the material, the more acoustic energy

it  can  withstand  before  bursting1.  Currently,  micro- bubble shells are composed of albumin, galactose, lipid,

or polymers 2.

 

•      Micro-bubble  gas  core:  The  gas  core  is  the  most important part of the ultrasound contrast micro-bubble because it determines the echogenicity. When gas bubbles are caught in an ultrasonic frequency field, they compress, oscillate, anreflect a  characteristic echo- this generates the strong and unique sonogram in contrast-enhanced ultrasound. Gas cores can be composed of air, or heavy gases like perfluorocarbon, or nitrogen2. Heavy gases are less water-soluble so they are less likely to leak out from the micro-bubble to impair echogenicity1 .Therefore, micro-bubbles with heavy gas cores are likely to last longer in circulation.

 

Safety of micro-bubbles

As with all pharmaceutical agents, micro-bubble agents have

to pass rigorous safety tests in order for them to be licensed. Extensive trials have established an excellent overall safety record with few significant adverse effects. However, there are some concerns that disruption of their outer shells produces local bioeffects such as sonoporation (subcellular membrane damage) and cell lysis at diagnostic frequencies and that perfluorocarbon gases enhance these effects. Despite this, no effects of these processes  have  been  observed  in  humans.  Concern about administering volumes of gas into the blood stream has been shown not to be an issue as the amount given is under 200 mL, too small to exhibit an effect. Overall, it has been shown that the safety of micro- bubbles compares favourably to that of conventional radiographic contrast agents and those used in contrast- enhanced MRI 3.

 

Working Of Contrast-Enhanced Ultrasound:

There are two forms of contrast-enhanced ultrasound, untargeted  (used  in  the  clinic  today)  and  targeted

(under preclinical development). The two methods slightly differ from each other.

 

Untargeted CEUS

Untargeted microbubbles, such as the aforementioned

Optison or Levovist, are injected intravenously into the systemic  circulation  in  a  small  bolus.  The microbubbles will remain in the systemic circulation fo  certain  period  of   time.   During  that   time, ultrasound waves are directed on the area of interest. When microbubbles in the blood flow past the imaging window, the microbubbles’ compressible gas cores oscillate in response to the high frequency sonic energy field, as described in the ultrasound article. The microbubbles reflect a unique echo that stands in stark contrast to the surrounding tissue due to the orders of magnitude mismatch between microbubble and tissue echogenicityThe  ultrasound  system  converts  the strong echogenicity into a contrast-enhanced image of the area of interest. In this way, the bloodstreams echo is enhanced, thus allowing the clinician to distinguish blood from surrounding tissues.

 

Targeted CEUS

Targeted  contrast-enhanced  ultrasound  works  in  a

similar fashion, with a few alterations. Microbubbles targeted   with   ligan that   bin certain   molecular markers that are expressed by the area of imaging interest are still injected systemically in a small bolus. Microbubbles theoretically travel through the circulatory system, eventually finding their respective targets and binding specifically. Ultrasound waves can then be directed on the area of interest. If a sufficient number of microbubbles have bound in the area, their compressible gas cores oscillate in response to the high frequency sonic energy field, as described in the ultrasound article. The targeted microbubbles also reflect a unique echo that stands in stark contrast to the surrounding tissue due to the orders of magnitude mismatch  between  microbubble  and  tissue echogenicity. The ultrasound system converts the strong echogenicity into a contrast-enhanced image of the area of interest, revealing the location of the bound microbubbles 4. Detection of bound microbubbles may then show that the area of interest is expressing that particular molecular, which can be indicative of a certain disease state, or identify particular cells in the area of interest.

 

Applications Of Contrast-Enhanced Ultrasound:

Untargeted contrast-enhanced ultrasound is currently applied in echocardiography. Targeted contrast-enhanced ultrasound is being developed for a variety of medical applications.

 

Untargeted CEUS

Untargeted  microbubbles  like  Optison  and  Levovist  are

currently used in echocardiography.

•      Organ Edge Delineation: microbubbles can enhance the  contrast  at  the  interface  between  the  tissue  and blood. A clearer picture of this interface gives the clinician a better picture of the structure of an organ. Tissue structure is crucial in echocardiograms, where a thinning, thickening, or  irregularity in  the  heart  wall indicates a serious heart condition that requires either monitoring or treatment.

 

•      Bloo Volum and   Perfusion contrast-enhanced ultrasound holds the promise for (1) evaluating the degree of blood perfusion in an organ or area of interest and (2) evaluating the blood volume in an organ or area of interest. When used in conjunction with Doppler Ultrasound, microbubbles can measure myocardial flow rate to diagnose valve problems. And the relative intensity of the microbubble echoes can also provide a quantitative estimate on blood volume.

 

Targeted CEUS

•     Inflammation in   inflammator disease suc as

Crohn’s disease, atherosclerosis, and even heart attacks, the inflamed blood vessels specifically express certain receptors like VCAM-1, ICAM-1, E-selectin. If microbubbles are targeted with ligands that bind these molecules,  they  can  be  used  in  contrast echocardiography to detect the onset of inflammation. Early detection allows the design of better treatments.

 

•      Cancer:  cancer  cells  also  express  a  specific  set  of receptors, mainly receptors that encourage angiogenesis, or the growth of new blood vessels. If microbubbles are targeted with ligands that bind receptors like VEGF, they can non-invasively and specifically identify areas of cancers.

 

•      Gene Delivery: Vector DNA can be conjugated to the microbubbles.   Microbubbles   can   b targeted   with ligands that bind to receptors expressed by the cell type of interest. When the targeted microbubble accumulates at the cell surface with its DNA payload, ultrasound can be used to burst the microbubble. The force associated with the bursting may temporarily permeablize surrounding tissues and allow the DNA to more easily enter the cells.

•      Drug Delivery: drugs can be incorporated into the microbubbles lipid shell. The microbubbles large size relative to other drug delivery vehicles like liposomes may allow a greater amount of drug to be  delivered per  vehicle. By targeted  the  drug- loaded microbubble with  ligands that bind  to  a specific  cell  type,  microbubble  will  not  only deliver the drug specifically, but can also provide verification that the drug is delivered if the area is imaged using ultrasound.

 

Advantages of Contrast-Enhanced Ultrasound:

On  top  of  the  strengths  mentioned  in  the  medical

sonography entry, contrast-enhanced ultrasound adds these additional advantages:

•      The body is 90% water, and therefore, acoustically homogeneous. Blood and surrounding tissues have similar echogenicities, so it is also difficult to clearly discern the degree of blood flow, perfusion, or the interface between the tissue and blood using traditional ultrasound 2

•      Ultrasound imaging allows real-time evaluation of blood flow 5.

•      Ultrasonic   molecular   imagin is   safer   than molecular imaging modalities such as radionuclide imaging because it does not involve radiation5.

•     Alternative molecular imaging modalities, such as

MRI,  PET,  and  SPECT  are  very  costly. Ultrasoundon  the  other  hand,  is  very  cost- efficient and widely available4.

•      Since  microbubbles  can  generate  such  strong signals,  a  lower  intravenous  dosage  is  needed,

micrograms of microbubbles are needed compared

to milligrams for other molecular imaging modalities such as MRI contrast agents 4.

•      Targeting strategies for microbubbles are versatile and modular. Targeting new area only entails conjugating a new ligand.

 

Disadvantages Of Contrast-Enhanced Ultrasound:

In addition to the weaknesses mentioned in the medical sonography entry, contrast-enhanced ultrasound suffers from the following disadvantages:

•      Microbubbles dont last very long in circulation. They have low circulation residence times because they either get taken up by immune system cells or get taken up by the liver or spleen even when they are coated with PEG 4.

•      Ultrasoun produces   mor heat   as   th frequency increases, so the ultrasonic frequency must be carefully monitored.

•      Microbubbles burst at low ultrasound frequencies and at high mechanical indices (MI), which is the measure of the  acoustic power output of  the  ultrasound imaging system. Increasing MI increases image quality, but there are  tradeoffs  with  microbubble  destruction. Microbubble destruction could cause local microvasculature ruptures and hemolysis 6

•      Targeting ligands can be immunogenic, since current targeting ligands used in preclinical experiments are derived from animal culture 6 .

•      Low targeted microbubble adhesion efficiency, which means a small fraction of injected microbubbles bind to the area of interest 7 This is one of the main reasons that targeted  contrast-enhanced ultrasounremains  in  the preclinical development stages.

 

REFERENCES:

1.    Eniola  AO  and.  Hammer  DA.  In  vitro  characterization  of leukocyte    mimetic    for    targeting    therapeutics    to    the endothelium  using  two  receptors.  Biomaterials.  2005;  26: 7136-44.

2.    Eniola AO, Willcox PJ and. Hammer DA. Interplay between rolling and firm adhesion elucidated with a cell-free system engineered with two distinct receptor-ligand pairs. Biophys. J. 2003; 85: 2720-31.

3.    Klibano AL Ligand-carryin gas-fille microbubbles: ultrasound  contrast  agents  for  targeted  molecular  imaging. Bioconjug Chem. 2005; 16: 9-17.

4.    Klibanov AL. Targeted delivery of gas-fillemicrospheres, contrast agents for ultrasound imaging. Adv Drug Deliv Rev. 1999; 37: 139-157.

5.  Lindner JR. Microbubbles in medical imaging: current applications  and  future  directions.  Nat  Rev  Drug  Discov. 2004; 3: 527-32.

6.    Lindner JR, Klibanov AL and Ley K. Targeting inflammation, In: Biomedical aspects of drug targeting. (Muzykantov, V.R., Torchilin, V.P., eds.) Kluwer, Boston, 2002; pp. 149-172.

7.    McCulloch MC, Gresser S, Moos J, Odabashian S, Jasper J, Bednarz P, Burgess D, Carney V, Moore E, Sisk A, Waggoner S, Witt and Adams D. Ultrasound contrast physics: A series on contrast echocardiography, article 3. J Am Soc Echocardiogr. 13: 959-67.

 

Received on 26.06.2008    Modified on 10.07.2008

Accepted on 10.08.200 © RJPT All right reserved

Research J. Pharm. and Tech. 1(3): July-Sept. 2008; Page 152-154